Likewise, we identified mutations in ID3 (L70P, P98R, Q100P) and TCF3 (N551K), which had been previously described, predominantly in Burkitt lymphoma, to confer dependence on PI3K pathway signaling, and may indicate a potential therapeutic vulnerability22. This evidence concerns the gene TCF3 and Burkitt lymphoma.